Mindbloom

Mindbloom
TypePrivate
IndustryTelehealth
Founded2018; 8 years ago (2018)
FoundersDylan Beynon
Area served
United States (35 states, incl. Washington, D.C.)[1]
Key people
Websitewww.mindbloom.com

Mindbloom is an American telemedicine company that treats anxiety and depression via ketamine-assisted therapy. It was founded in 2018 by Dylan Beynon. The company has contributed to studies researching the effectiveness of ketamine as a treatment for mental health related issues.

History

Mindbloom was founded in late 2018 by Dylan Beynon, an entrepreneur, who also serves as the company's chief executive officer.[2] Beynon previously co-founded Mighty, a legal technology company, with Joshua Schwadron.[3] Beynon was influenced to create Mindbloom through his family's history of mental illness and his own positive experiences with psychedelic medicines.[4]

In September 2019, Mindbloom became an exclusively virtual business.[5] In March 2020, Mindbloom opened an in-person clinic on New York's Fifth Avenue, which was described in a Forbes article as the city's "first legal, upscale guided psychedelic therapy center".[6] Not long after the center's opening, the governor's office of New York issued the PAUSE order in response to the severity of the COVID-19 pandemic, closing all non-essential businesses,[7] causing the company to pivot back to a remote model. Mindbloom, among other telehealth providers, ultimately expanded during the COVID-19 pandemic, partially due to federal officials relaxing rules on telehealth and mailing controlled substances[8] through the temporary suspension of the Ryan Haight Act, a law passed in 2008.[9] In 2022, it was reported in The Wall Street Journal that Mindbloom had hired former House representative Greg Walden for the purpose of lobbying on telehealth policies.[10]

In November 2023, Mindbloom released its Mastermind Series, an episodic therapy program. Each episode addresses a specific issue and is led by its own mental health professional.[11]

Protocol

Patients must first receive approval from a psychiatric clinician certified to prescribe ketamine. In 2021, Mindbloom reported that it denied approximately 35% of applicants to its programs, which included potential cases where symptoms either weren’t severe enough or were too severe for at-home treatment.[2] Other reasons for denial include previously diagnosed substance use disorder, psychosis, and uncontrolled hypertension.[12] New patient programs begin with six ketamine-assisted therapy sessions.[11]

Patients are shipped dissolvable tablets, slow-release lozenges, or faster-acting injectables containing ketamine for use at home. Another household member is expected to be present during use. A trained mental health professional is present via video conference for the first dose.[13][8] In addition to the medicine, patients are shipped a sleep mask, journal, and blood pressure cuff to monitor their vitals before and after a session.[14] The medicine and additional components are shipped in a branded "Bloombox".[15] Mindbloom also provides a curated soundtrack for patients to listen to during a session.[14] Through the company's mobile app, patients can reach out to clinicians during their treatment, or, access "interactive educational content for use before or after" their sessions.[16]

Other employees, known as "psychedelic guides", meet with patients virtually before and after sessions to process their experiences. Despite there being no formal requirements to become a psychedelic guide, a majority of guides have completed trainings in some form of mental health, life coaching, or crisis management.[2]

Studies

In 2022, a study was published in the Journal of Affective Disorders, testing the effectiveness of at-home ketamine therapy for treating depression and anxiety, using data from 1,247 Mindbloom patients. This was the largest study regarding the safety and efficacy of ketamine treatments at the time of its publishing. The results showed that 62.8% of patients with depression and 62.9% of patients with anxiety experienced improvement in their symptoms within four weeks, while less than 1% of patients saw their symptoms worsen. 88.6% of patients in the study reported an improvement in their symptoms, with 9.3% of that total accounting for a delayed improvement. The study lacked a control group for comparison and contained limited follow-up data.[17]

In 2024, a follow-up study was published, also in the Journal of Affective Disorders. In a sample of 11,441 Mindbloom patients, 56.4% of those experiencing depression reported an improvement in their symptoms, while 28.1% reported remission in their depressive symptoms after 4 sessions. Among patients who experienced anxiety-related symptoms, 56.1% reported an improvement, while 28.8% of patients reported remission in those symptoms after 4 sessions. Less than 5% of patients responded negatively to the treatment. The study lacked a control group and a fixed dosage of medicine, and showed a drop-off in follow-up data after 4 weeks. The study also found that "mutual activation of depressed mood and anhedonia had a substantial role in maintaining depression despite ongoing treatment."[18]

Litigation

In June 2025, Mindbloom filed a defamation lawsuit in Delaware Superior Court against Dow Jones & Company, publisher of The Wall Street Journal, alleging that a 2024 article falsely implied that Mindbloom was connected to the death of actor Matthew Perry. The complaint stated that Perry had never been a Mindbloom client and had not received ketamine or other treatment from the company or its affiliated clinicians.[19] A spokesperson for The Wall Street Journal denied the allegations and described the lawsuit as meritless.[20]

In October 2025, John Ward, acting on behalf of the estate of his son Phillip Ward, filed a wrongful-death lawsuit against Mindbloom and related defendants in Pitt County, North Carolina. The lawsuit alleged that Mindbloom failed to properly screen Ward before providing at-home ketamine treatment and continued supplying ketamine despite missed appointments and other alleged warning signs. Mindbloom denied wrongdoing, with CEO Dylan Beynon stating that the facts would show the company provided appropriate care.[21]

References

  1. ^ Gilbert, Daniel (30 December 2022). "This doctor prescribes ketamine to thousands online. It's all legal". The Washington Post.
  2. ^ a b c Dodge, David (4 November 2021). "The Ketamine Cure". New York Times.
  3. ^ Weinberger, Matt (6 March 2018). "This startup just got $114 million to help people get 'a better deal from the justice system' by finding investors for their lawsuits". Business Insider. Axel Springer SE.
  4. ^ Draffin, Leslie (13 October 2021). "At-home ketamine treatment helping people with anxiety, depression". KCEN-TV. NBC.
  5. ^ Harnish, Amelia (20 March 2021). "Is tripping with a therapist the next big thing In mental health?". Business Insider. Axel Springer SE.
  6. ^ Hasse, Javier (10 March 2020). "Upscale Psychedelics Therapy Center Opens On New York's 5th Avenue". Forbes.
  7. ^ "Governor Cuomo Signs the 'New York State on PAUSE' Executive Order". Governor Andrew M. Cuomo. March 20, 2020. Archived from the original on March 28, 2020. Retrieved July 23, 2020.
  8. ^ a b Yup, Kayla (16 August 2024). "People Are Injecting Ketamine at Home". Wall Street Journal.
  9. ^ Huet, Ellen (14 November 2022). "Online Ketamine Clinics Face Tougher Times After Covid-Era Boom". Bloomberg.
  10. ^ Essley Whyte, Liz; Winkler, Rolfe; Abbott, Brianna (25 November 2022). "Telehealth Companies Lobby to Extend Pandemic-Era Rules". Wall Street Journal.
  11. ^ a b Goldstein, Lara (29 November 2023). "EXCLUSIVE: Mindbloom's Mastermind Series, A Psychedelic Therapy Program For Heartbreak, Burnout & Parallel Challenges". Benzinga.
  12. ^ Abbott, Brianna; Hernandez, Daniela (30 October 2022). "Americans Take Ketamine at Home for Depression With Little Oversight". Wall Street Journal.
  13. ^ Collins, Sonya (19 January 2024). "Your employer may be adding another health benefit to its roster: psychedelic drugs". Fortune.
  14. ^ a b Singer, Maya (12 February 2021). "Could the Embrace of Psychedelics Lead to a Mental-Health Revolution?". Vogue.
  15. ^ Donohue, Meg (5 January 2024). "I Tried At-Home Ketamine Therapy—and It Wasn't What I Expected". Elle.
  16. ^ Wang, Nick (26 August 2021). "The Psychedelic Revolution Will Be App-ified". Multidisciplinary Association for Psychedelic Studies.
  17. ^ Hull, Thomas D.; Malgaroli, Matteo; Gazzaley, Adam; Akiki, Teddy J.; Madan, Alok; Vando, Leonardo; Arden, Kristin; Swain, Jack; Klotz, Madeline; Paleos, Casey (1 October 2022). "At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial". Journal of Affective Disorders. 314: 59–67. doi:10.1016/j.jad.2022.07.004. ISSN 0165-0327. PMID 35809678.
  18. ^ Mathai, David S.; Hull, Thomas D.; Vando, Leonardo; Malgaroli, Matteo (15 September 2024). "At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data". Journal of Affective Disorders. 361: 198–208. doi:10.1016/j.jad.2024.05.131. ISSN 0165-0327. PMC 11284959. PMID 38810787.
  19. ^ Matthew Church (June 7, 2025). "Mindbloom Review". ChoosingTherapy.com. Retrieved June 13, 2025.
  20. ^ "Wall Street Journal denies falsely linking ketamine therapy provider to Matthew Perry's death". Courthouse News Service. June 3, 2025. Retrieved June 13, 2025.
  21. ^ Team, WITN Web (2025-10-24). "Ketamine provider responds to lawsuit filed in death of Greenville man". WCTI-TV. Retrieved 2026-06-24.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.